Discover GammaDelta Therapeutics
GammaDelta Therapeutics is committed to transforming the treatment of patients living with haematological and solid cancers. Our mission is to develop the first effective off the shelf cancer therapy based on one of the body’s own immune cells, a subtype of gamma delta (γδ) T lymphocyte known as Vδ1+ T cell.
About GammaDelta Therapeutics
GammaDelta Therapeutics is a biotechnology company headquartered in the UK. We are the only company with the capability to deliver both blood and tissue (skin) derived allogeneic cell therapies for the treatment of haematological and solid cancers using a unique subtype of gamma delta T lymphocyte (γδ T cell or γδ T lymphocyte) known as Vδ1+ T cells.
Our technologies are based upon pioneering world-class research conducted by Professor Adrian Hayday and Dr Oliver Nussbaumer, at King’s College London and the Francis Crick Institute, and Professor Bruno Silva-Santos at the University of Lisbon.
A look inside the science
Gamma delta T lymphocytes (γδ T cells) represent a potentially transformative advance in the treatment of malignant diseases. GammaDelta Therapeutics is harnessing the unique properties of these cells, which combine the specificity of adaptive immunity with the speed of an innate cellular response, to develop potent and targeted solid tumour and haematological cancer therapies.
Treatments using blood or tissue derived γδ T cells are suitable for use in allogeneic therapy and are unaffected by common issues associated with autologous, antigen-dependent approaches that may lead to toxicity, loss of efficacy or therapeutic resistance
Partners & Investors
GammaDelta Therapeutics is building partnerships with some of the most prestigious Institutions in oncology, immune therapy and life science investors.